

***Clostridioides difficile***  
**infection, *Escherichia coli***  
**bacteraemia,**  
***Staphylococcus aureus***  
**bacteraemia and Surgical**  
**Site Infection in Scotland**

**October to December 2022**

Publication date: 04 April 2023

## This is an Official Statistics Publication

**The Official Statistics (Scotland) Order 2008** authorises NHS National Services Scotland (the legal name being the Common Services Agency for the Scottish Health Service) to produce official statistics.

All official statistics should comply with the UK Statistics Authority's Code of Practice which promotes the production and dissemination of official statistics that inform decision making. They can be formally assessed by the UK Statistics Authority's regulatory arm for National Statistics status.

Find out more about the Code of Practice at:

<https://code.statisticsauthority.gov.uk/>

Find out more about official statistics at:

<https://uksa.statisticsauthority.gov.uk/about-the-authority/uk-statistical-system/producers-of-official-statistics/>

## Contents

Introduction	3
Main Points	4
Results and Commentary	6
<i>Clostridioides difficile</i> Infection (CDI)	6
<i>Escherichia coli</i> bacteraemia (ECB)	14
<i>Staphylococcus aureus</i> bacteraemia (SAB)	21
Surgical Site Infection (SSI)	28
List of Tables	29
Contact	31
Further Information	31
Rate this publication	31
Appendices	32
Appendix 1 – Background information	32
Revisions to the surveillance	32
Report methods and caveats	35
UK comparisons	35
Appendix 2 – Publication Metadata	37
Appendix 3 – Early access details	48
Appendix 4 – ARHAI Scotland and Official Statistics	49

### Introduction

Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Scotland provides a commentary on quarterly epidemiological data in Scotland for October to December (Q4) 2022 on the following:

- *Clostridioides difficile* infection
- *Escherichia coli* bacteraemia
- *Staphylococcus aureus* bacteraemia
- Surgical Site Infection

Data are provided for the 14 NHS boards and one NHS Special Health Board.

## Main Points

### ***Clostridioides difficile* infection (CDI) during October to December 2022**

- The total number of CDI cases in patients reported to ARHAI was 256.
- 212 CDI cases were reported to ARHAI as healthcare associated. This corresponds to an incidence rate of 13.5 cases per 100,000 total occupied bed days (TOBDs).
- 44 CDI cases were reported as community associated. This corresponds to an incidence rate of 3.2 cases per 100,000 population.
- NHS Highland was above the 95% confidence interval upper limit for healthcare associated CDI in the funnel plot analysis.
- No NHS boards were above normal variation for healthcare or community associated CDI when analysing trends over the past three years.

### ***Escherichia coli* bacteraemia (ECB) during October to December 2022**

- The total number of ECB cases in patients reported to ARHAI was 1,044.
- 541 ECB cases were reported to ARHAI as healthcare associated. This corresponds to an incidence rate of 34.5 cases per 100,000 TOBDs.
- 503 ECB cases were reported as community associated. This corresponds to an incidence rate of 36.4 cases per 100,000 population.
- NHS Forth Valley and NHS Tayside were above the 95% confidence interval upper limit for healthcare associated ECB in the funnel plot analysis.
- NHS Ayrshire and Arran was above the 95% confidence interval upper limit for community associated ECB in the funnel plot analysis.
- No NHS boards were above normal variation for community or healthcare associated ECB when analysing trends over the past three years.

### ***Staphylococcus aureus* bacteraemia (SAB) during October to December 2022**

- The total number of SAB cases in patients reported to ARHAI was 433.
- 302 SAB cases were reported to ARHAI as healthcare associated. This corresponds to an incidence rate of 19.2 cases per 100,000 TOBDs.
- 131 SAB cases were reported as community associated. This corresponds to an incidence rate of 9.5 cases per 100,000 population.
- No NHS boards were above the 95% confidence interval upper limit for healthcare or community associated SAB in the funnel plot analysis.
- No NHS boards were above normal variation for community or healthcare associated SAB when analysing trends over the past three years.

### **Surgical Site Infection (SSI) October to December 2022**

Epidemiological data for SSI are not included for this quarter due to the pausing of surveillance to support the COVID-19 response.

## Results and Commentary

### *Clostridioides difficile* Infection (CDI)

#### Total Cases for Quarter

- During Q4 2022, 256 *Clostridioides difficile* infection (CDI) cases in patients were reported to ARHAI. In the previous quarter there were 284 cases.
- There was a single isolate that was resistant to metronidazole. All isolates were susceptible to vancomycin.

#### Healthcare associated infection cases by NHS board where specimen taken

- During Q4 2022, 212 CDI cases were reported to ARHAI as healthcare associated. This corresponds to an incidence rate of 13.5 cases per 100,000 total occupied bed days (TOBDs) (**Table 1**).
- Yearly trends (comparing year-ending December 2021 with year-ending December 2022) show that there was a decrease in NHS Greater Glasgow & Clyde and in Scotland overall (**Table 2**).
- NHS Highland was above the 95% confidence interval upper limit in the funnel plot analysis (**Figure 1**).
- No NHS boards were above normal variation when analysing trends over the past three years (see **supplementary data**).

### Community associated infection cases by NHS board of residence

- During Q4 2022, 44 CDI cases were reported as community associated. This corresponds to an incidence rate of 3.2. cases per 100,000 population and is a decrease compared to the Q3 2022 incidence rate of 5.9 cases per 100,000 population. (**Table 3**).
- Yearly trends (comparing year-ending December 2021 with year-ending December 2022) show that there were no increases or decreases in NHS boards or Scotland overall (**Table 4**).
- No NHS boards were above the 95% confidence interval upper limit in the funnel plot analysis (**Figure 2**).
- No NHS boards were above normal variation when analysing trends over the past three years (see **supplementary data**).



**Table 1: CDI cases and incidence rates (per 100,000 TOBDs) for healthcare associated infection cases: Q3 2022 (July to September 2022) compared to Q4 2022 (October to December 2022).<sup>1,2,3</sup>**

NHS Board	Q3 Cases	Q3 Bed Days	Q3 Rate	Q4 Cases	Q4 Bed Days	Q4 Rate
AA	18	115,947	15.5	20	119,580	16.7
BR	5	31,443	15.9	1	32,790	3.0
DG	6	46,399	12.9	5	46,878	10.7
FF	9	89,390	10.1	8	91,962	8.7
FV	10	77,214	13.0	19	79,270	24
GJ	2	12,653	15.8	0	13,327	0.0
GR	11	132,436	8.3	4	132,046	3.0
GGC	54	439,126	12.3	63	443,639	14.2
HG	14	76,066	18.4	22	75,533	29.1
LN	29	147,577	19.7	29	149,515	19.4
LO	30	244,423	12.3	29	248,852	11.7
OR	1	3,388	29.5	1	3,151	31.7
SH	0	2,788	0.0	0	2,878	0.0
TY	13	120,417	10.8	10	123,441	8.1
WI	0	6,470	0.0	1	6,190	16.2
<b>Scotland</b>	<b>202</b>	<b>1,545,737</b>	<b>13.1</b>	<b>212</b>	<b>1,569,052</b>	<b>13.5</b>

1. An arrow denotes statistically significant change.
2. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & Total occupied bed days: Information Services Division ISD(S)1.
3. Figures include any updates received following the last publication (see Appendix 2).

**Table 2: CDI cases and incidence rates (per 100,000 TOBDs) for healthcare associated infection cases: year-ending Decembr 2021 (YE Q4 21) compared to year-ending December 2022 (YE Q4 22).<sup>1,2,3</sup>**

NHS Board	YE Q4 21 Cases	YE Q4 21 Bed Days	YE Q4 21 Rate	YE Q4 22 Cases	YE Q4 22 Bed Days	YE Q4 22 Rate
AA	101	422,039	23.9	83	462,500	17.9
BR	7	117,864	5.9	12	127,812	9.4
DG	27	164,404	16.4	26	180,487	14.4
FF	31	329,119	9.4	31	353,986	8.8
FV	29	282,384	10.3	49	305,913	16.0
GJ	1	49,178	2.0	2	50,493	4.0
GR	54	474,166	11.4	43	521,238	8.2
GGC	259	1,610,601	16.1	225	1,726,504	↓ 13.0
HG	57	272,580	20.9	62	294,700	21.0
LN	114	546,936	20.8	102	583,564	17.5
LO	132	944,831	14.0	123	977,350	12.6
OR	0	12,098	0.0	4	13,203	30.3
SH	4	8,887	45.0	3	10,354	29.0
TY	39	437,217	8.9	49	478,891	10.2
WI	3	23,857	12.6	4	25,179	15.9
<b>Scotland</b>	<b>858</b>	<b>5,696,161</b>	<b>15.1</b>	<b>818</b>	<b>6,112,174</b>	<b>↓ 13.4</b>

1. An arrow denotes statistically significant change.
2. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & Total occupied bed days: Information Services Division ISD(S)1.
3. Figures include any updates received following the last publication (see Appendix 2).

**Table 3: CDI cases and incidence rates (per 100,000 population) for community associated infection cases: Q3 2022 (July to September 2022) compared to Q4 2022 (October to December 2022).<sup>1,2,3,4</sup>**

NHS Board	Q3 Cases	Q3 Population	Q3 Rate	Q4 Cases	Q4 Population	Q4 Rate
AA	8	368,690	8.6	4	368,690	4.3
BR	1	116,020	3.4	1	116,020	3.4
DG	7	148,790	18.7	1	148,790	2.7
FF	2	374,730	2.1	2	374,730	2.1
FV	0	305,710	0.0	2	305,710	2.6
GR	8	586,530	5.4	5	586,530	3.4
GGC	17	1,185,040	5.7	6	1,185,040	2.0
HG	10	324,280	12.2	6	324,280	7.3
LN	6	664,030	3.6	6	664,030	3.6
LO	15	916,310	6.5	8	916,310	3.5
OR	0	22,540	0.0	0	22,540	0.0
SH	0	22,940	0.0	2	22,940	34.6
TY	7	417,650	6.6	1	417,650	0.9
WI	1	26,640	14.9	0	26,640	0.0
<b>Scotland</b>	<b>82</b>	<b>5,479,900</b>	<b>5.9</b>	<b>44</b>	<b>5,479,900</b>	<b>↓ 3.2</b>


1. An arrow denotes statistically significant change.
2. Quarterly population rates are based on an annualised population.
3. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & National Records of Scotland (NRS) mid-year population estimates.
4. Figures include any updates received following the last publication (see Appendix 2).

**Table 4: CDI cases and incidence rates (per 100,000 population) for community associated infection cases: year-ending December 2021 (YE Q4 21) compared to year-ending December 2022 (YE Q4 22).<sup>1,2,3</sup>**

NHS Board	YE Q4 21 Cases	YE Q4 21 Population	YE Q4 21 Rate	YE Q4 22 Cases	YE Q4 22 Population	YE Q4 22 Rate
AA	28	368,690	7.6	22	368,690	6.0
BR	3	116,020	2.6	4	116,020	3.4
DG	16	148,790	10.8	10	148,790	6.7
FF	14	374,730	3.7	10	374,730	2.7
FV	2	305,710	0.7	2	305,710	0.7
GR	22	586,530	3.8	25	586,530	4.3
GGC	55	1,185,040	4.6	41	1,185,040	3.5
HG	19	324,280	5.9	26	324,280	8.0
LN	35	664,030	5.3	27	664,030	4.1
LO	67	916,310	7.3	49	916,310	5.3
OR	2	22,540	8.9	1	22,540	4.4
SH	0	22,940	0.0	2	22,940	8.7
TY	12	417,650	2.9	12	417,650	2.9
WI	2	26,640	7.5	4	26,640	15.0
<b>Scotland</b>	<b>277</b>	<b>5,479,900</b>	<b>5.1</b>	<b>235</b>	<b>5,479,900</b>	<b>4.3</b>


1. An arrow denotes statistically significant change.
2. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & NRS mid-year population estimates.
3. Figures include any updates received following the last publication (see Appendix 2).

**Figure 1: Funnel plot of CDI incidence rates (per 100,000 TOBD) in healthcare associated infection cases for all NHS boards in Scotland in Q4 2022.<sup>1,2</sup>**



1. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & Total occupied bed days: Information Services Division ISD(S)1.
2. NHS Shetland and NHS Golden Jubilee overlap.

**Figure 2: Funnel plot of CDI incidence rates (per 100,000 population) in community associated infection cases for all NHS boards in Scotland in Q4 2022.<sup>1,2</sup>**



1. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & NRS mid-year population estimates.
2. NHS Orkney and NHS Western Isles overlap, as do NHS Borders and NHS Dumfries and Galloway.

## ***Escherichia coli* bacteraemia (ECB)**

### **Total Cases for Quarter**

- During Q4 2022, 1,044 *Escherichia coli* bacteraemia (ECB) cases in patients were reported to ARHAI. In the previous quarter there were 1,137 cases.

### **Healthcare associated infection cases by NHS board where specimen taken**

- During Q4 2022, 541 ECB cases were reported to ARHAI as healthcare associated. This corresponds to an incidence rate of 34.5 cases per 100,000 TOBDs (**Table 5**).
- Yearly trends (comparing year-ending December 2021 with year-ending December 2022) show that there were decreases in NHS Ayrshire and Arran, NHS Borders, NHS Highland, NHS Lothian and in Scotland overall (**Table 6**).
- NHS Forth Valley and NHS Tayside were above the 95% confidence interval upper limit in the funnel plot analysis (**Figure 3**).
- No NHS boards were above normal variation when analysing trends over the past three years (see **supplementary data**).

### **Community associated infection cases by NHS board of residence**

- During Q4 2022, 503 ECB cases were reported as community associated. This corresponds to an incidence rate of 36.4 cases per 100,000 population and is a decrease compared to the Q3 2022 incidence rate of 41.8 cases per 100,000. (**Table 7**).
- Yearly trends (comparing year-ending December 2021 with year-ending December 2022) show that there was an increase in NHS Fife, and there was a decrease in NHS Western Isles. (**Table 8**).
- NHS Ayrshire and Arran was above the 95% confidence interval upper limit in the funnel plot analysis (**Figure 4**).

- No NHS boards were above normal variation when analysing trends over the past three years (see [supplementary data](#)).

**Table 5: ECB cases and incidence rates (per 100,000 TOBD) for healthcare associated infection cases: Q3 2022 (July to September 2022) compared to Q4 2022 (October to December 2022).<sup>1,2,3</sup>**

NHS Board	Q3 Cases	Q3 Bed Days	Q3 Rate	Q4 Cases	Q4 Bed Days	Q4 Rate
AA	43	115,947	37.1	35	119,580	29.3
BR	13	31,443	41.3	12	32,790	36.6
DG	21	46,399	45.3	20	46,878	42.7
FF	33	89,390	36.9	28	91,962	30.4
FV	44	77,214	57.0	40	79,270	50.5
GJ	2	12,653	15.8	2	13,327	15.0
GR	42	132,436	31.7	49	132,046	37.1
GGC	156	439,126	35.5	139	443,639	31.3
HG	14	76,066	18.4	14	75,533	18.5
LN	60	147,577	40.7	59	149,515	39.5
LO	60	244,423	24.5	70	248,852	28.1
OR	1	3,388	29.5	4	3,151	126.9
SH	3	2,788	107.6	3	2,878	104.2
TY	59	120,417	49.0	64	123,441	51.8
WI	9	6,470	139.1	2	6,190	32.3
<b>Scotland</b>	<b>560</b>	<b>1,545,737</b>	<b>36.2</b>	<b>541</b>	<b>1,569,052</b>	<b>34.5</b>

1. An arrow denotes statistically significant change.
2. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & Total occupied bed days: Information Services Division ISD(S)1.
3. Figures include any updates received following the last publication (see Appendix 2).



**Table 6: ECB cases and incidence rates (per 100,000 TOBDs) for healthcare associated infection cases: year-ending December 2021 (YE Q4 21) compared to year-ending December 2022 (YE Q4 22).<sup>1,2,3</sup>**

NHS Board	YE Q4 21 Cases	YE Q4 21 Bed days	YE Q4 21 Rate	YE Q4 22 Cases	YE Q4 22 Bed days	YE Q4 22 Rate
AA	200	422,039	47.4	170	462,500	↓ 36.8
BR	54	117,864	45.8	38	127,812	↓ 29.7
DG	58	164,404	35.3	73	180,487	40.4
FF	127	329,119	38.6	123	353,986	34.7
FV	144	282,384	51.0	166	305,913	54.3
GJ	3	49,178	6.1	6	50,493	11.9
GR	175	474,166	36.9	181	521,238	34.7
GGC	548	1,610,601	34.0	540	1,726,504	31.3
HG	78	272,580	28.6	56	294,700	↓ 19.0
LN	211	546,936	38.6	223	583,564	38.2
LO	295	944,831	31.2	249	977,350	↓ 25.5
OR	7	12,098	57.9	8	13,203	60.6
SH	9	8,887	101.3	11	10,354	106.2
TY	192	437,217	43.9	222	478,891	46.4
WI	12	23,857	50.3	15	25,179	59.6
<b>Scotland</b>	<b>2113</b>	<b>5,696,161</b>	<b>37.1</b>	<b>2081</b>	<b>6,112,174</b>	<b>↓ 34.0</b>

1. An arrow denotes statistically significant change.
2. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & Total occupied bed days: Information Services Division ISD(S)1.
3. Figures include any updates received following the last publication (see Appendix 2).

**Table 7: ECB cases and incidence rates (per 100,000 population) for community associated infection cases: Q3 2022 (July to September 2022) compared to Q4 2022 (October to December 2022).<sup>1,2,3,4</sup>**

NHS Board	Q3 Cases	Q3 Population	Q3 Rate	Q4 Cases	Q4 Population	Q4 Rate
AA	43	368,690	46.3	51	368,690	54.9
BR	17	116,020	58.1	9	116,020	30.8
DG	22	148,790	58.7	23	148,790	61.3
FF	52	374,730	55.1	38	374,730	40.2
FV	32	305,710	41.5	31	305,710	40.2
GR	56	586,530	37.9	41	586,530	27.7
GGC	119	1,185,040	39.8	104	1,185,040	34.8
HG	28	324,280	34.3	33	324,280	40.4
LN	94	664,030	56.2	73	664,030	43.6
LO	81	916,310	35.1	57	916,310	24.7
OR	4	22,540	70.4	4	22,540	70.4
SH	1	22,940	17.3	3	22,940	51.9
TY	28	417,650	26.6	35	417,650	33.2
WI	0	26,640	0.0	1	26,640	14.9
<b>Scotland</b>	<b>577</b>	<b>5,479,900</b>	<b>41.8</b>	<b>503</b>	<b>5,479,900</b>	<b>↓ 36.4</b>


1. An arrow denotes statistically significant change.
2. Quarterly population rates are based on an annualised population.
3. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & NRS mid-year population estimates.
4. Figures include any updates received following the last publication (see Appendix 2).

**Table 8: ECB cases and incidence rates (per 100,000 population) for community associated infection cases: year-ending December 2021 (YE Q4 21) compared to year-ending December 2022 (YE Q4 22).<sup>1,2,3</sup>**

NHS Board	YE Q4 21 Cases	YE Q4 21 Population	YE Q4 21 Rate	YE Q4 22 Cases	YE Q4 22 Population	YE Q4 22 Rate
AA	216	368,690	58.6	197	368,690	53.4
BR	50	116,020	43.1	52	116,020	44.8
DG	96	148,790	64.5	79	148,790	53.1
FF	139	374,730	37.1	178	374,730	↑ 47.5
FV	107	305,710	35.0	118	305,710	38.6
GR	194	586,530	33.1	176	586,530	30.0
GGC	452	1,185,040	38.1	437	1,185,040	36.9
HG	115	324,280	35.5	114	324,280	35.2
LN	294	664,030	44.3	322	664,030	48.5
LO	317	916,310	34.6	296	916,310	32.3
OR	10	22,540	44.4	11	22,540	48.8
SH	8	22,940	34.9	7	22,940	30.5
TY	165	417,650	39.5	145	417,650	34.7
WI	15	26,640	56.3	5	26,640	↓ 18.8
<b>Scotland</b>	<b>2,178</b>	<b>5,479,900</b>	<b>39.7</b>	<b>2,137</b>	<b>5,479,900</b>	<b>39.0</b>


1. An arrow denotes statistically significant change.
2. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & NRS mid-year population estimates.
3. Figures include any updates received following the last publication (see Appendix 2).

**Figure 3: Funnel plot of ECB incidence rates (per 100,000 TOBD) in healthcare associated infection cases for all NHS boards in Scotland in Q4 2022.<sup>1</sup>**



1. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & Total occupied bed days: Information Services Division ISD(S)1.

**Figure 4: Funnel plot of ECB incidence rates (per 100,000 population) in community associated infection cases for all NHS boards in Scotland in Q4 2022.<sup>1,2</sup>**



1. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & NRS mid-year population estimates.
2. NHS Forth Valley and NHS Highland overlap.

## ***Staphylococcus aureus* bacteraemia (SAB)**

### **Total cases for quarter**

- During Q4 2022, 433 *Staphylococcus aureus* bacteraemia (SAB) cases in patients were reported to ARHAI. In the previous quarter there were 385 SAB cases.

### **Healthcare associated infection cases by NHS board where specimen taken**

- During Q4 2022, 302 SAB cases were reported to ARHAI as healthcare associated. This corresponds to an incidence rate of 19.2 cases per 100,000 TOBDs (**Table 9**).
- Yearly trends (comparing year-ending December 2021 with year-ending December 2022) show that there were no increases or decreases in NHS boards or Scotland overall (**Table 10**).
- No NHS boards were above the 95% confidence interval upper limit in the funnel plot analysis (**Figure 5**).
- No NHS boards were above normal variation when analysing trends over the past three years (see **supplementary data**).

### **Community associated infection cases by NHS board of residence**

- During Q4 2022, 131 SAB cases were reported as community associated. This corresponds to an incidence rate of 9.5 cases per 100,000 population (**Table 11**).
- Yearly trends (comparing year-ending December 2021 with year-ending December 2022) show that there were decreases in NHS Lanarkshire and NHS Tayside (**Table 12**).
- No NHS boards were above the 95% confidence interval upper limit in the funnel plot analysis (**Figure 6**).
- No NHS boards were above normal variation when analysing trends over the past three years (see **supplementary data**).

**Table 9: SAB cases and incidence rates (per 100,000 TOBDs) for healthcare associated infection cases: Q3 2022 (July to September 2022) compared to Q4 2022 (October to December 2022).<sup>1,2,3</sup>**

NHS Board	Q3 Cases	Q3 Bed Days	Q3 Rate	Q4 Cases	Q4 Bed Days	Q4 Rate
AA	15	115,947	12.9	29	119,580	24.3
BR	4	31,443	12.7	7	32,790	21.3
DG	11	46,399	23.7	8	46,878	17.1
FF	14	89,390	15.7	10	91,962	10.9
FV	6	77,214	7.8	14	79,270	17.7
GJ	4	12,653	31.6	1	13,327	7.5
GR	19	132,436	14.3	32	132,046	24.2
GGC	85	439,126	19.4	86	443,639	19.4
HG	5	76,066	6.6	14	75,533	18.5
LN	27	147,577	18.3	24	149,515	16.1
LO	40	244,423	16.4	42	248,852	16.9
OR	2	3,388	59.0	0	3,151	0.0
SH	0	2,788	0.0	3	2,878	104.2
TY	31	120,417	25.7	30	123,441	24.3
WI	1	6,470	15.5	2	6,190	32.3
<b>Scotland</b>	<b>264</b>	<b>1,545,737</b>	<b>17.1</b>	<b>302</b>	<b>1,569,052</b>	<b>19.2</b>

1. An arrow denotes statistically significant change.
2. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & Total occupied bed days: Information Services Division ISD(S)1.
3. Figures include any updates received following the last publication (see Appendix 2).

**Table 10: SAB cases and incidence rates (per 100,000 TOBDs) for healthcare associated infection cases: year-ending December 2021 (YE Q4 21) compared to year-ending December 2022 (YE Q4 22).<sup>1,2,3</sup>**

NHS Board	YE Q4 21 Cases	YE Q4 21 Bed days	YE Q4 21 Rate	YE Q4 22 Cases	YE Q4 22 Bed days	YE Q4 22 Rate
AA	62	422,039	14.7	83	462,500	17.9
BR	24	117,864	20.4	21	127,812	16.4
DG	27	164,404	16.4	36	180,487	19.9
FF	44	329,119	13.4	50	353,986	14.1
FV	53	282,384	18.8	46	305,913	15.0
GJ	14	49,178	28.5	11	50,493	21.8
GR	98	474,166	20.7	94	521,238	18.0
GGC	306	1,610,601	19.0	315	1,726,504	18.2
HG	47	272,580	17.2	46	294,700	15.6
LN	105	546,936	19.2	96	583,564	16.5
LO	143	944,831	15.1	147	977,350	15.0
OR	0	12,098	0.0	5	13,203	37.9
SH	3	8,887	33.8	5	10,354	48.3
TY	101	437,217	23.1	107	478,891	22.3
WI	8	23,857	33.5	7	25,179	27.8
<b>Scotland</b>	<b>1,035</b>	<b>5,696,161</b>	<b>18.2</b>	<b>1,069</b>	<b>6,112,174</b>	<b>17.5</b>

1. An arrow denotes statistically significant change.
2. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & Total occupied bed days: Information Services Division ISD(S)1.
3. Figures include any updates received following the last publication (see Appendix 2).



**Table 11: SAB cases and incidence rates (per 100,000 population) for community associated infection cases: Q3 2022 (July to September 2022) compared to Q4 2022 (October to December 2022).<sup>1,2,3,4</sup>**

NHS Board	Q3 Cases	Q3 Population	Q3 Rate	Q4 Cases	Q4 Population	Q4 Rate
AA	13	368,690	14.0	9	368,690	9.7
BR	4	116,020	13.7	1	116,020	3.4
DG	7	148,790	18.7	4	148,790	10.7
FF	12	374,730	12.7	15	374,730	15.9
FV	6	305,710	7.8	6	305,710	7.8
GR	15	586,530	10.1	17	586,530	11.5
GGC	15	1,185,040	5.0	19	1,185,040	6.4
HG	8	324,280	9.8	11	324,280	13.5
LN	9	664,030	5.4	15	664,030	9.0
LO	28	916,310	12.1	20	916,310	8.7
OR	1	22,540	17.6	1	22,540	17.6
SH	1	22,940	17.3	0	22,940	0.0
TY	2	417,650	1.9	13	417,650	12.3
WI	0	26,640	0.0	0	26,640	0.0
<b>Scotland</b>	<b>121</b>	<b>5,479,900</b>	<b>8.8</b>	<b>131</b>	<b>5,479,900</b>	<b>9.5</b>


1. An arrow denotes statistically significant change.
2. Quarterly population rates are based on an annualised population.
3. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & NRS mid-year population estimates.
4. Figures include any updates received following the last publication (see Appendix 2).

**Table 12: SAB cases and incidence rates (per 100,000 population) for community associated infection cases: year-ending December 2021 (YE Q4 21) compared to year-ending December 2022 (YE Q4 22).<sup>1,2,3</sup>**

NHS Board	YE Q4 21 Cases	YE Q4 21 Population	YE Q4 21 Rate	YE Q4 22 Cases	YE Q4 22 Population	YE Q4 22 Rate
AA	46	368,690	12.5	43	368,690	11.7
BR	16	116,020	13.8	12	116,020	10.3
DG	27	148,790	18.1	25	148,790	16.8
FF	38	374,730	10.1	48	374,730	12.8
FV	29	305,710	9.5	32	305,710	10.5
GR	59	586,530	10.1	69	586,530	11.8
GGC	81	1,185,040	6.8	72	1,185,040	6.1
HG	35	324,280	10.8	32	324,280	9.9
LN	80	664,030	12.0	52	664,030	↓ 7.8
LO	88	916,310	9.6	96	916,310	10.5
OR	0	22,540	0.0	4	22,540	17.7
SH	3	22,940	13.1	2	22,940	8.7
TY	52	417,650	12.5	32	417,650	↓ 7.7
WI	2	26,640	7.5	2	26,640	7.5
<b>Scotland</b>	<b>556</b>	<b>5,479,900</b>	<b>10.1</b>	<b>521</b>	<b>5,479,900</b>	<b>9.5</b>


1. An arrow denotes statistically significant change.
2. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & NRS mid-year population estimates.
3. Figures include any updates received following the last publication (see Appendix 2).

**Figure 5: Funnel plot of SAB incidence rates (per 100,000 TOBD) in healthcare associated infection cases for all NHS boards in Scotland in Q4 2022.<sup>1,2</sup>**



1. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & Total occupied bed days: Information Services Division ISD(S)1.
2. NHS Ayrshire & Arran, NHS Grampian and NHS Tayside overlap, as do NHS Forth Valley and NHS Highland.

**Figure 6: Funnel plot of SAB incidence rates (per 100,000 population) in community associated infection cases for all NHS boards in Scotland in Q4 2022.<sup>1,2</sup>**



1. Source of data is Electronic Communication of Surveillance in Scotland (ECOSS) & NRS mid-year population estimates.
2. NHS Shetland and NHS Western Isles overlap.

## **Surgical Site Infection (SSI)**

Epidemiological data for SSI are not included for this quarter due to the pausing of surveillance to support the COVID-19 response.

## List of Tables

File name	File and size
Table 1: CDI cases and incidence rates (per 100,000 TOBDs) for healthcare associated infection cases: Q3 2022 (July to September 2022) compared to Q4 2022 (October to December 2022).	supplementary data (486 Kb)
Table 2: CDI cases and incidence rates (per 100,000 TOBDs) for healthcare associated infection cases: year-ending December 2021 (YE Q4 21) compared to year-ending December 2022 (YE Q4 22).	supplementary data (486 Kb)
Table 3: CDI cases and incidence rates (per 100,000 population) for community associated infection cases: Q3 2022 (July to September 2022) compared to Q4 2022 (October to December 2022).	supplementary data (486 Kb)
Table 4: CDI cases and incidence rates (per 100,000 population) for community associated infection cases: year-ending December 2021 (YE Q4 21) compared to year-ending December 2022 (YE Q4 22).	supplementary data (486 Kb)
Table 5: ECB cases and incidence rates (per 100,000 TOBD) for healthcare associated infection cases: Q3 2022 (July to September 2022) compared to Q4 2022 (October to December 2022).	supplementary data (486 Kb)
Table 6: ECB cases and incidence rates (per 100,000 TOBDs) for healthcare associated infection cases: year-ending December 2021 (YE Q4 21) compared to year-ending December 2022 (YE Q4 22).	supplementary data (486 Kb)
Table 7: ECB cases and incidence rates (per 100,000 population) for community associated infection cases: Q3 2022 (July to September 2022) compared to Q4 2022 (October to December 2022).	supplementary data (486 Kb)
Table 8: ECB cases and incidence rates (per 100,000 population) for community associated infection cases: year-ending December 2021 (YE Q4 21) compared to year-ending December 2022 (YE Q4 22).	supplementary data (486 Kb)
Table 9: SAB cases and incidence rates (per 100,000 TOBDs) for healthcare associated infection cases: Q3 2022 (July to September 2022) compared to Q4 2022 (October to December 2022).	supplementary data (486 Kb)
Table 10: SAB cases and incidence rates (per 100,000 TOBDs) for healthcare associated infection cases: year-ending December 2021 (YE Q4 21) compared to year-ending December 2022 (YE Q4 22).	supplementary data (486 Kb)

<b>File name</b>	<b>File and size</b>
<b>Table 11: SAB cases and incidence rates (per 100,000 population) for community associated infection cases: Q3 2022 (July to September 2022) compared to Q4 2022 (October to December 2022).</b>	<b>supplementary data (486 Kb)</b>
<b>Table 12: SAB cases and incidence rates (per 100,000 population) for community associated infection cases: year-ending December 2021 (YE Q4 21) compared to year-ending December 2022 (YE Q4 22).</b>	<b>supplementary data (486 Kb)</b>

## Contact

**Shona Cairns, Consultant Healthcare Scientist, ARHAI Scotland**

Phone: 0141 300 1922

Email: [NSS.ARHAIdatateam@nhs.scot](mailto:NSS.ARHAIdatateam@nhs.scot)

## Further Information

Further information can be found on the [ARHAI Scotland website](#).

The data from this publication is available to download [from our web page](#) along with background information and metadata.

For more information on types of infections included in this report, please see the [CDI](#), [ECB](#), [SAB](#) and [SSI](#) pages.

The next release of this publication will be July 2023.

## Rate this publication

Please [provide feedback](#) on this publication to help us improve our services.



## Appendices

### Appendix 1 – Background information

#### Revisions to the surveillance

Description of Revision	First report revision applied	Report section(s) revision applies to	Rational for revision
Addition of healthcare/ community case assignment	October 2017	CDI/SAB	An increasing awareness of those infections occurring in community settings has warranted measurement of incidence rates by healthcare setting (healthcare settings vs. community settings) to enable interventions to be targeted to the relevant settings.
Use of standardised denominator data for CDI/ECB/SAB	October 2017	CDI/SAB	<p>The 'total occupied bed days' data will be extracted from the ISD(S)1 data collection which contains aggregated information on acute and non-acute bed days including geriatric medicine and long-term stays in real-time.</p> <p>The standardisation of denominator data across the three surveillance programmes could result in slightly less accurate denominators due to inclusion of persons in the denominator who are at slightly lower risk of infection. However, in surveillance programmes developed for the purpose of preventing infection and driving quality improvement in care, consistency of the denominators over time tend to be more important than getting a very precise estimate of the population at risk, as the primary aim is to reduce infection to a lower incidence relative to what it was at the initial time of benchmarking.</p>

Description of Revision	First report revision applied	Report section(s) revision applies to	Rational for revision
Reporting of CDI cases aged 15 years and above only	October 2017	CDI	Current Scottish Government Local Delivery Plan Standards are based on the incidence rate in cases aged 15 years and above, therefore the report has been aligned to reflect this. ARHAI will continue to monitor CDI incidence rates in the separate age groups (15-64 years and 65 years and above) internally.
Reporting of total SAB cases only (i.e. Removal of MRSA sub-analysis)	October 2017	SAB	MRSA numbers are becoming too small to carry out statistical analysis. ARHAI will continue to monitor internally.
Name change for <i>Clostridium difficile</i> to <i>Clostridioides difficile</i> .	October 2018	CDI	A novel genus <i>Clostridioides</i> has been proposed for <i>Clostridium difficile</i> which will now be known as <i>Clostridioides difficile</i> . There are no implications with regards to the natural history of infection, infection prevention and control, or clinical treatment. <a href="https://www.sciencedirect.com/science/article/pii/S1075996416300762?via%3Dihub">https://www.sciencedirect.com/science/article/pii/S1075996416300762?via%3Dihub</a>
Addition of year end trends to ECB	October 2018	ECB	This analysis (already included for other reported organisms) is now possible for ECB due the amount of data that has now been collected.
Change in production of Quarterly SPC Charts	April 2020	All sections	Updated method used for calculating exceptions within the SPC charts. The mean, Trigger/warning lines (+2 standard deviations) and upper control limits (+3 standard deviations) presented, are now calculated using the 12 quarters prior to the most recent quarter, as to compare the new rate against an existing baseline.
Changes to data collection in	July 2020	All sections	A CNO letter sent 25th March 2020 asked NHS Boards to continue to report case numbers and origin of infection data but they would not be

Description of Revision	First report revision applied	Report section(s) revision applies to	Rational for revision
response to COVID-19			<p>required to report risk factor data as would normally be expected under enhanced/extended surveillance for <i>Staphylococcus aureus</i> bacteraemia (SAB), <i>Escherichia coli</i> bacteraemia (ECB) and <i>Clostridioides difficile</i> infection (CDI).</p> <p>All mandatory and voluntary Surgical Site Infection (SSI) surveillance was paused until further notice.</p>
Change from Health Protection Scotland to ARHAI Scotland	October 2020	All sections	<p>In April 2020, as part of launch of Public Health Scotland, the ARHAI Group within Health Protection Scotland (HPS) became ARHAI Scotland.</p> <p>ARHAI Scotland will continue to support NHS boards in the prevention and control of healthcare associated infections. The report was updated to reflect this branding change.</p>
Change from National Waiting Times Centre (NWTC) to NHS Golden Jubilee (GJ)	January 2021	All sections	Labelling updated.
Change to reporting of ribotypes	October 2022	CDI	A description of CDI ribotypes (RTs) has not been included in the report since October 2022. The CDI typing service provided by the Scottish Microbiology Reference Laboratory (SMiRL) is currently being reviewed.
Recommencement of mandatory surveillance	April 2023	All sections	As part of a return to pre-pandemic surveillance, for data collected from October 2022 onwards enhanced/extended surveillance

Description of Revision	First report revision applied	Report section(s) revision applies to	Rational for revision
following COVID-19 response			<p>for <i>Escherichia coli</i> bacteraemia (ECB) and <i>Staphylococcus aureus</i> bacteraemia (SAB) has been reinstated. Mandatory surveillance of enhanced fields including source of infection/entry point and risk factors as appropriate has resumed in line with the bacteraemia surveillance protocol.</p> <p>Previously, for data collected from 25 March 2020 onwards, only origin of infection was mandatory for ECB and SAB surveillance.</p> <p>Meanwhile all mandatory and voluntary Surgical Site Infection (SSI) surveillance will remained paused until further notice.</p>

## Report methods and caveats

Full details of the report methods and caveats can be found [here](#).

## UK comparisons

Improved collaboration with the other UK nations has made comparisons and standardisation across the UK a high priority for all four nations' governments/health departments. The changes introduced in the Scottish HAI surveillance, described here facilitate benchmarking of the Scottish data against those of the rest of the UK.

## Key to NHS boards

AA = NHS Ayrshire & Arran

BR = NHS Borders

DG = NHS Dumfries & Galloway

FV = NHS Forth Valley

FF = NHS Fife

GJ = NHS Golden Jubilee

GR = NHS Grampian

GGC = NHS Greater Glasgow & Clyde

HG = NHS Highland

LN = NHS Lanarkshire

LO = NHS Lothian

OR = NHS Orkney

SH = NHS Shetland

TY = NHS Tayside

WI = NHS Western Isles

## Appendix 2 – Publication Metadata

### Publication title

Quarterly epidemiological data on *Clostridioides difficile* infection, *Escherichia coli* bacteraemia, *Staphylococcus aureus* bacteraemia and Surgical Site Infection in Scotland

### Description

This release provides information on *Clostridioides difficile* infection, *Escherichia coli* bacteraemia, *Staphylococcus aureus* bacteraemia and Surgical Site Infection in Scotland for the period October to December 2022.

### Theme

Infections in Scotland

### Topic

*Clostridioides difficile* infection, *Escherichia coli* bacteraemia, *Staphylococcus aureus* bacteraemia and Surgical Site Infection

### Format

MS Word reports and MS Excel workbooks

### Data source(s)

#### ***Clostridioides difficile* infection:**

**Case data source:** Electronic Communication of Surveillance in Scotland (ECOSS)

**Data linkage source:** General / Acute Inpatient and Day Case Scottish Morbidity Records (SMR01)

**Healthcare associated denominator:** Total occupied bed days: Information Services Division ISD(S)1

**Community associated denominator:** National Records of Scotland (NRS) mid-year population estimates

***Escherichia coli* bacteraemia:**

**Case data source:** Electronic Communication of Surveillance in Scotland (ECOSS) Enhanced Surveillance Web Tool

**Healthcare associated denominator:** Total occupied bed days: Information Services Division ISD(S)1

**Community associated denominator:** NRS mid-year population estimates

***Staphylococcus aureus* bacteraemia:**

**Case data source:** Electronic Communication of Surveillance in Scotland (ECOSS) Enhanced Surveillance Web Tool

**Healthcare associated denominator:** Total occupied bed days: Information Services Division ISD(S)1

**Community associated denominator:** NRS mid-year population estimates

**Surgical Site Infection:**

**Case data source:** Surgical Site Infection Reporting System (SSIRS)

**Number of procedures denominator:** SSIRS

**Date that data are acquired**

The date the data were extracted for analysis.

*Clostridioides difficile*: 19/01/2023

*Escherichia coli* Bacteraemia: 24/02/2023

*Staphylococcus aureus* Bacteraemia: 24/02/2023

Surgical Site Infection: Epidemiological data for SSI are not included for this quarter due to the pausing of surveillance to support the COVID-19 response.

### **Release date**

04 April 2023

### **Frequency**

Quarterly

### **Timeframe of data and timeliness**

The latest iteration of data is 31 December 2022, therefore the data are three months in arrears.

### **Continuity of data**

Quarterly as at March, June, September, December

### **Revisions statement**

These data are not subject to planned major revisions. However, ARHAI aims to continually improve the interpretation of the data and therefore analysis methods are regularly reviewed and may be updated in the future.

### **Revisions relevant to this publication**

Updates to previously published figures

### **Total Occupied Bed Days (TOBDs)**

Amendments to total occupied bed days dataset provided by Information Services Division (ISD) have been included in historic dataset for analysis and reporting. Updated figures are available to view in the most recent [supplementary data](#).

Quarter	NHS Board	Previous TOBDs	Updated TOBDs
2022 Q3	FF	89,316	89,390

### ***Clostridioides difficile* Infection (CDI)**

Data linkage between CDI surveillance data and the Scottish Morbidity Records (SMR01) is used to identify community and healthcare associated CDI cases. Delays in SMR01 data availability at the time of report production means that some cases may be reassigned as



either healthcare associated or community associated CDI at a later date (see **Methods and Caveats**).

There were no retrospective amendments to the data.

### ***Escherichia coli* Bacteraemia (ECB)**

There were no retrospective amendments to the data.

### ***Staphylococcus aureus* Bacteraemia (SAB)**

There were no retrospective amendments to the data.

### **Surgical Site Infection (SSI)**

Epidemiological data for SSI are not included for this quarter due to the pausing of surveillance to support the COVID-19 response.

### **Concepts and definitions**

#### ***Clostridioides difficile* Infection (CDI)**

*Clostridioides difficile* infection (CDI) is the most common cause of intestinal infections (and diarrhoea) associated with antimicrobial therapy. Clinical disease comprises a range of toxin mediated symptoms from mild diarrhoea, which can resolve without treatment, to severe cases such as pseudomembranous colitis (PMC), toxic megacolon and peritonitis that can lead to death.

For mild disease, diarrhoea is usually the only symptom. Other clinical features consistent with more severe forms of CDI include fever, leukocytosis, pseudomembranous colitis and ileus.

Symptoms of CDI, and associated immune reactions in children differ from those in adults, but the pathology is not well described. Routine testing in children aged less than 3 years old is not recommended.

Approximately 3% of healthy adults and 20% of hospital patients carry *C. difficile* in their gut. The elderly living in care homes or staying in long-term care facilities are more likely to carry

*C. difficile* than other adults. In studies from the US, 20% of care home residents and 50% of patients in long-term care facilities, respectively, were colonised with *C. difficile*.

The Scottish CDI guidance 'Guidance on Prevention and Control of CDI in Healthcare Settings in Scotland' and *C. difficile* testing protocol 'protocol for diagnosis of CDI' are key documents for the control and reduction of CDI in Scotland.

There remains scope for a reduction of incidence rates through continued local monitoring, appropriate prescribing, and compliance with infection prevention and control measures.

### ***Escherichia coli* Bacteraemia (ECB)**

*Escherichia coli* (*E. coli*) is a bacterium commonly found in the gut of animals and people where it forms part of the normal gut flora that helps human digestion. Although most types of *E. coli* live harmlessly in your gut, some types can make you unwell. Some types of *E. coli* can cause urinary tract infections (UTI) and illnesses such as pneumonia.

*E. coli* continues to be the most frequent cause of Gram-negative bacteraemia in Scotland and is a frequent cause of infection worldwide.

New cases of ECB are identified by laboratory testing (via positive blood cultures) and submitted to the national system ECOSS. Only cases of ECB that have been reviewed and confirmed by the NHS boards in the enhanced surveillance system are included in the quarterly commentaries.

### ***Staphylococcus aureus* Bacteraemia (SAB)**

*Staphylococcus aureus* (*S. aureus*) is a Gram-positive bacterium which colonises the nasal cavity of about a quarter of the healthy population. This colonisation is usually harmless. However, infection can occur if *S. aureus* breaches the body's defence systems and can cause a range of illnesses from minor skin infections to serious systemic infections such as bacteraemia. Some strains of *S. aureus* produce toxins or show resistance to first line treatments therefore can be more complicated to treat.

Scotland has had a mandatory meticillin resistant *S. aureus* (MRSA) bacteraemia surveillance programme since 2001. The programme was extended to include meticillin sensitive *S. aureus*

(MSSA) bacteraemias in 2006 and in 2014 to include enhanced *S. aureus* bacteraemia (SAB) surveillance. Full details of the surveillance methods may be found in the protocol.

### **Surgical Site Infection (SSI)**

A surgical site infection (SSI) is an infection that occurs after surgery in the part of the body where the surgery took place. SSI may be superficial infections involving the skin only, while other SSI is more serious and can involve tissues under the skin, organs, or implanted material.

SSI is one of the most common types of healthcare associated infection in Scotland, estimated to account for 16.5% of inpatient healthcare associated infection within NHSScotland, according to Scottish Point Prevalence Survey 2016. Surgical Site Infection Surveillance (SSIS) is mandatory across NHSScotland and all NHS boards participate in SSI surveillance for all inpatient and post discharge surveillance (PDS) for 10 post-operative days for caesarean section procedures and prospective readmission surveillance for hip arthroplasty for 30 post-operative days. Additional new mandatory large bowel and vascular procedures commenced since April 2017. Reporting these procedures will not take place until it is assessed that robust data have been provided by boards.

Further information on the methods and caveats for can be found [here](#).

When a board is highlighted as an exception this will be looked at further as per the exception reporting process.

Further information on the production of quarterly exception reports (SOP) can be found [here](#).

### **Relevance and key uses of the statistics**

#### ***Clostridioides difficile* Infection (CDI)**

Surveillance data is essential for monitoring trends and assisting in outbreak investigations. Certain strains of *C. difficile* have been associated with more severe disease (e.g. PCR types 027 and 078) and antibiotic resistance has been suggested to be a factor in the emergence and spread of *C. difficile* epidemic types. In addition, the identification of ribotypes and whole genome sequencing can assist in the investigation of outbreaks.

The surveillance data should inform and support NHS boards in implementing antimicrobial prescribing policies, infection control and prevention interventions.

### ***Escherichia coli* Bacteraemia (ECB)**

The outputs of the surveillance programme are intended to support the NHS boards in controlling and reducing the burden of ECB. Benchmarking against other NHS boards (and other countries) is an important function of the surveillance. In conjunction with other sources of intelligence (including enhanced surveillance data) the outputs of the quarterly surveillance can also help the NHS boards with planning and targeting activities to reduce risk to patient of becoming infected and improve the care of patients (i.e. strategic planning, targeted intervention, care quality improvement).

As urinary tract infections are commonly associated with *E. coli* bacteraemia cases, ARHAI Scotland coordinates the sharing of urinary tract infection (UTI) reduction resources. These include the National Hydration Campaign which aims to convey the public health benefits of good hydration in terms of UTI prevention, and the National Catheter Passport which gives information on how to care for urinary catheters at home as well as a clinical section for a nurse, doctor or carer. Work is also being done on improving antimicrobial treatment of people with infections – co-ordinated by the Scottish Antimicrobial Prescribing Group (SAPG) through a network of antimicrobial management teams.

### ***Staphylococcus aureus* Bacteraemia (SAB)**

ARHAI continues to offer support to NHS boards across Scotland to aid their local SAB reduction strategies. A programme of enhanced SAB surveillance commenced in all NHS boards in Scotland on 1 October 2014. This is providing further intelligence to focus future reduction interventions.

### **Surgical Site Infection (SSI)**

SSIs are estimated to double the length of post-operative stay in hospital and significantly increase the cost of care. The national SSIS programme is intended to enhance the quality of patient care with use of data obtained from surveillance to compare incidence of SSI over time

and against a benchmark rate and to use this information locally to review and guide clinical practice.

### **Accuracy**

CDI, ECB and SAB data are the product of the Electronic Communication of Surveillance in Scotland (ECOSS). Participating laboratories routinely report all identifications of organisms, infection or microbiological intoxication, unless they are known to be of no clinical or public health importance. The collected data is used for: the identification of single cases of severe disease, outbreaks, and longer term trends in the incidence of laboratory reported infections, enhanced surveillance, health protection, analytical and statistical use.

Delays in SMR01 data availability at the time of report production means that some CDI cases may be reassigned at a later date. Therefore, healthcare-associated and community-associated CDI cases in this report are provisional and may change as more data becomes available.

The enhanced ECB and SAB ECOSS web tool has built-in validation rules that have to be met before the data is submitted. Further checks of the data are made by ARHAI before the data are analysed. CDI validation of collected data entails sending a list of CDI cases extracted from ECOSS and asking for confirmation that the cases represent true CDI cases, i.e., meet the case definition which is defined in the surveillance protocol sent to all the NHS boards and available on the [website](#). The final list of CDI cases is then agreed before publishing.

SSI data comes from the Surgical Site Infection Reporting System (SSIRS). Complying with a national minimum dataset and definitions for Surgical Site Infections, enables the data submitted to Health Protection Scotland to be mapped into the national dataset following a rigorous quality assurance process.

SSIRS has built-in validation rules and data cannot be submitted until rules are met. SSIRS primary validation checks for incomplete or ambiguous core data fields, for example, if presentation to the surgery is 'emergency' the OPCS code should correspond. Secondary validation includes data checks that can be accepted without completion and/or values that are outside the stated requirements.

### **Completeness**

#### **ECB/SAB:**

Surveillance data are collected using an ECOSS Surveillance Web Tool that allows data collectors in NHS boards to validate ECOSS records as well as additional cases that may not be included in the ECOSS system. This therefore means that completeness is near to 100%. Only cases reviewed in the enhanced surveillance are included in the 'analysis' in the commentary publication.

#### **CDI:**

Diagnosis of CDI is confirmed in a patient who is both symptomatic with diarrhoea and whose stool has tested positive using a two-step diagnostic algorithm. Laboratory reports of positive samples are then sent to ECOSS for data extraction. In the community, patients with CDI may have a mild illness that does not require a GP visit, or the symptoms may not be recognised by a GP for a *C. difficile* test request. In hospitals, the chance of a diarrhoea sample not being tested for *C. difficile* is much lower, and patients who have ileus (i.e., CDI but with no diarrhoea) might be missed; however, as a result of ARHAI published guidance on managing CDI patients, this is not likely. ARHAI carries out validation with the NHS boards to check that no CDI cases have been missed from ECOSS each quarter. As with most surveillance programmes, completeness will not be 100% but mandatory surveillance, supported by ARHAI through issued guidance on diagnosis of CDI and validation of cases, ensures this is as near to 100% as practically possible. When categorising by healthcare or community, not all cases may be successfully data linked in any one quarter. Therefore, the sum total of the healthcare and community CDI cases may not equal the total number of CDI cases reported to ARHAI.

#### **SSI:**

Surveillance coordinators are responsible for completeness and accuracy of data. At hospital level, processes are in place to ensure all patients included in the standard surveillance have had forms completed (e.g. cross checking with admission or theatre list). ARHAI also compare SSIRS data with data from ISD to make sure all procedures under surveillance have been included; however, this comparison is only done annually.

### **Comparability**

#### **CDI / ECB / SAB:**

Public Health England report rates per quarter for CDI, ECB and SAB (methods and definitions may differ) – <https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-and-c-difficile-infection-quarterly-epidemiological-commentary>

#### **SSI:**

SSI rates by health board are not published by the rest of UK. Annual numbers are reported by Public Health England - <https://www.gov.uk/government/publications/surgical-site-infections-ssi-surveillance-nhs-hospitals-in-england>

### **Accessibility**

It is the policy of ARHAI to make its web sites and products accessible according to **published guidelines**.

### **Coherence and clarity**

Tables and charts are accessible via the ARHAI Scotland website at:

<https://www.nss.nhs.scot/publications/quarterly-epidemiological-data-on-clostridioides-difficile-infection-escherichia-coli-bacteraemia-staphylococcus-aureus-bacteraemia-and-surgical-site-infection-in-scotland-october-to-december-q4-2022/>

### **Value type and unit of measurement**

Healthcare associated cases and incidence rates (per 100,000 Total occupied bed days (TOBDs)) for *Clostridioides difficile* infection, *Escherichia coli* bacteraemia & *Staphylococcus aureus* bacteraemia.

Community associated cases and incidence rates (per 100,000 population) for *Clostridioides difficile* infection, *Escherichia coli* bacteraemia & *Staphylococcus aureus* bacteraemia.

Number of procedures and Surgical Site Infections and incidence per categories (per 100 procedures) for inpatients and post discharge surveillance.

**Disclosure**

The PHS protocol on Statistical Disclosure Protocol is followed

<https://publichealthscotland.scot/publications/statistical-disclosure-protocol/>

**Official Statistics designation**

Official Statistics

**UK Statistics Authority Assessment**

Not Assessed

**Last published**

17 January 2023

**Next published**

July 2023

**Date of first publication**

7 April 2015

Prior to this *Clostridioides difficile* infection (first publication - 2 Apr 2008) and *Staphylococcus aureus* bacteraemia (first publication - 3 Apr 2002) were separate reports.

**Help email**

[NSS.ARHAIdatateam@nhs.scot](mailto:NSS.ARHAIdatateam@nhs.scot)

**Date form completed**

04 April 2023



## Appendix 3 – Early access details

### **Pre-Release Access**

Under terms of the "Pre-Release Access to Official Statistics (Scotland) Order 2008", ARHAI is obliged to publish information on those receiving Pre-Release Access ("Pre-Release Access" refers to statistics in their final form prior to publication). The standard maximum Pre-Release Access is five working days. Shown below are details of those receiving standard Pre-Release Access.

### **Standard Pre-Release Access:**

- Scottish Government Health Department
- NHS Board Chief Executives
- NHS Board Communication leads

### Appendix 4 – ARHAI Scotland and Official Statistics

#### About ARHAI Scotland

ARHAI Scotland works at the very heart of the health service across Scotland, delivering services critical to frontline patient care and supporting the efficient and effective operation of NHS Scotland.

#### Official Statistics

Our statistics comply with the **Code of Practice for Statistics** in terms of trustworthiness, high quality and public value. This also means that we keep data secure at all stages, through collection, processing, analysis and output production, and adhere to the **‘five safes’**.